Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 2004

View Archived Issues

Three novel series of vanilloid VR1 antagonists presented by GSK

New melanocortin MC4 agonists under study at Merck

Abbott researchers describe new dopamine D3 ligands for schizophrenia and depression

Novel Chk1 inhibitors and their use covered by AstraZeneca patent

New tubulin polymerization inhibitors prepared and tested at Aventis

AstraZeneca scientists design novel gamma-secretase inhibitors

Novel CDK2/CDK5 inhibitors claimed by IRM researchers

Bile acid transport inhibitors may lower plasma cholesterol levels

A3 adenosine receptor agonist inhibits the development of experimental arthritis in vivo

Novel hypoxia-targeting agents for tumor therapy

Orphan drug designation for BAY-43-9006 for renal cell carcinoma

European launch for Angiox

Further restructuring at Savient

Aridol asthma test meets endpoints in phase III study

Provenge extends survival of advanced prostate cancer patients in phase III study

Tumor responses in phase I study of Proxinium for head and neck cancer

Recent progress with Imvamune

ARRIVE 2 registry program begins enrollment

Enrollment completed in phase II Pneumocystis carinii study of DB-289

Delay to roflumilast regulatory filing in U.S.

Roche and Pharmasset to develop new generation HCV therapies

Mimpara approved in Europe

BAL-4079 enters phase III for severe chronic hand dermatitis

Novel platelet-specific nitric acid donor inhibits experimental thrombogenesis

Insulin enhances memory, mood in healthy subjects

OPC-28326 reduces the frequency of secondary RP attacks in patients with scleroderma

BPC-157 improves myofibrotic contracture in animal model

Mechanism of action of DMARD T-614

New data on the effects of the antisense inhibitor ISIS-301012

Abatacept effective in RA patients inadequately responding to methotrexate or TNF-alpha inhibitors

Laquinimod pharmacokinetics assessed in relapsing multiple sclerosis patients

Interleukin-12 produces responses in non-Hodgkin's lymphoma patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...